Published in Schweiz Rundsch Med Prax on January 14, 1992
The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol (1994) 2.04
Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem (1993) 1.57
Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochim Biophys Acta (1995) 1.16
Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J (1994) 1.15
Apolipoprotein B metabolism in homozygous familial hypercholesterolemia. J Lipid Res (1989) 1.09
Asymptomatic bacteriuria in diabetes mellitus. N Engl J Med (1967) 1.05
Low density lipoprotein causes general cellular activation with increased phosphatidylinositol turnover and lipoprotein catabolism. Proc Natl Acad Sci U S A (1988) 1.00
Differences in lipoprotein subfraction composition and distribution between type I diabetic men and control subjects. Diabetes (1990) 0.96
Relationship between plasma insulin levels and high density lipoprotein cholesterol levels in healthy men. Diabetologia (1981) 0.95
Characterization of a human high density lipoprotein-associated protein, NA1/NA2. Identity with SP-40,40, an inhibitor of complement-mediated cytolysis. Arterioscler Thromb (1991) 0.94
Protein heterogeneity of lipoprotein particles containing apolipoprotein A-I without apolipoprotein A-II and apolipoprotein A-I with apolipoprotein A-II isolated from human plasma. J Lipid Res (1988) 0.90
[Dyslipidemia in the diabetic patient. Recommendations of ALFEDIAM (French Language Association for the Study of Diabetes and Metabolic Diseases)]. Diabete Metab (1995) 0.85
Treatment of hyperlipoproteinemia (HLP) type II A with a new phenoxy-isobuturic acid derivative, procetofen. Int J Clin Pharmacol Biopharm (1979) 0.85
Lipoprotein (a) and vascular disease in diabetic patients. Diabetologia (1995) 0.83
Immunoaffinity fractionation of high-density lipoprotein subclasses 2 and 3 using anti-apolipoprotein A-I and A-II immunosorbent gels. Biochim Biophys Acta (1989) 0.82
Liver glycerokinase deficiency in man with hyperglycerolaemia and hypertriglyceridaemia. Eur J Clin Invest (1984) 0.81
Distribution of apolipoprotein E between free and A-II complexed forms in very-low- and high-density lipoproteins: functional implications. Biochim Biophys Acta (1991) 0.81
Iron excess, early glucose intolerance and impaired insulin secretion in idiopathic haemochromatosis. Eur J Clin Invest (1973) 0.81
HDL lipids in close relatives of coronary heart disease patients. Environmental and genetic influences. Atherosclerosis (1979) 0.81
HDL particle associated proteins in plasma and cerebrospinal fluid: identification and partial sequencing. Appl Theor Electrophor (1988) 0.81
Immunofractionation of high density lipoprotein subclasses 2 and 3. Similarities and differences of fractions isolated from male and female populations. Atherosclerosis (1990) 0.80
Metabolic effects of dietary fiber from dehulled soybeans in humans. Am J Clin Nutr (1983) 0.80
[Apoprotein E (apo E) phenotype and serum lipids in diabetics]. Schweiz Med Wochenschr (1987) 0.79
Phenotyping is an accurate means of analysing the principal apolipoprotein E isoforms. Clin Chim Acta (1994) 0.78
High density lipoprotein cholesterol in male relatives of patients with coronary heart disease. Atherosclerosis (1979) 0.78
Apolipoprotein E polymorphism as a risk factor for vascular disease in diabetic patients. Diabetes Care (1995) 0.78
Postprandial lipemia differentially influences high density lipoprotein subpopulations LpAI and LpAI,AII. J Lipid Res (1994) 0.78
The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients. Diabetologia (1991) 0.78
Acquired (secondary) forms of hypertriglyceridemia. Am J Cardiol (1991) 0.77
Underexpression of the apolipoprotein E4 isoform in an Italian population. Arterioscler Thromb (1993) 0.77
Factors influencing the low density lipoprotein profile in type 2 diabetic patients. Diabet Med (1995) 0.77
Apoprotein D in a healthy, male population and in male myocardial infarction patients and their male, first-degree relatives. Atherosclerosis (1986) 0.77
HDL and coronary heart disease: a familial trend. Adv Exp Med Biol (1987) 0.77
Decreased HDL cholesterol in prepubertal and pubertal children of CHD patients. Atherosclerosis (1980) 0.76
HDL cholesterol levels in patients with myocardial infarction and their families. Atherosclerosis (1986) 0.76
Gender differences in a type 2 (non-insulin-dependent) diabetic population with respect to apolipoprotein E phenotype frequencies. Diabetologia (1993) 0.76
Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level. Am J Ophthalmol (1994) 0.75
Marked changes of lipid levels during puberty in a patient with lipoprotein lipase deficiency. Eur J Pediatr (1997) 0.75
[Dietary lipids and serum lipids in adolescents, based on the Geneva study of the precursors of atherosclerosis]. Soz Praventivmed (1984) 0.75
[Prediabetes and early diabetes]. Pol Tyg Lek (1966) 0.75
Interference of dimethyl alpha-(dimethoxyphosphinyl) p-chlorobenzyl phosphate (SR-202) in thyroid hormone metabolism: evidence of inhibition of monodeiodination. J Endocrinol (1987) 0.75
[Hypercholesteremia: a problem of daily practice]. Rev Med Suisse Romande (1968) 0.75
[Diet in the treatment of hyperlipidaemia (author's transl)]. Ther Umsch (1980) 0.75
[The development of an extensive dissecting aneurysm of the aorta]. Rev Med Suisse Romande (1965) 0.75
[Diagnosis and treatment of hyperlipoproteinemias]. Schweiz Med Wochenschr (1972) 0.75
[Treatment of systemic lupus erythematosus with antimetabolites. Relations between the clinical course and immunological reactions]. Helv Med Acta Suppl (1967) 0.75
Early capillary changes in diabetes mellitus. Acta Diabetol Lat (1971) 0.75
[HDL and lipoproteins in the families of coronary patients]. Schweiz Med Wochenschr (1981) 0.75
Immunological confirmation of the presence of NA1/NA2 (cytolysis inhibitor) in cerebrospinal fluid. Schweiz Arch Neurol Psychiatr (1991) 0.75
Topical timolol maleate might adversely affect serum lipoproteins. Int Ophthalmol (1993) 0.75
[High-density lipoproteins in children with coronary diseases]. Helv Paediatr Acta (1981) 0.75
The influence of metabolic control on very low density lipoprotein composition in hypertriglyceridemic type II diabetics. A study using heparin-sepharose chromatography. Metabolism (1988) 0.75
Clofibrate, nephrotic syndrome, and histological changes in muscle. Lancet (1973) 0.75
[Hyperlipemia and diabetes]. Schweiz Med Wochenschr (1976) 0.75
Apparent lack of influence of the genetic drug oxidation status on plasma cholesterol concentration in man. Pharmacol Res Commun (1984) 0.75
[Dyslipidemias and diabetes mellitus]. Journ Annu Diabetol Hotel Dieu (1989) 0.75
Preparative isoelectrofocusing and high resolution 2-dimensional gel electrophoresis for concentration and purification of proteins. Appl Theor Electrophor (1991) 0.75
Geneva study on the precursors of atherosclerosis: first results. Soz Praventivmed (1979) 0.75
Lipoprotein complexes in human cerebrospinal fluid. Schweiz Arch Neurol Psychiatr (1993) 0.75
[Comparison of 2 cholesterol synthesis inhibitors (simvastatin and pravastatin)]. Schweiz Med Wochenschr (1993) 0.75
[Coronary insufficiency, hyperlipemia and diabetes]. Journ Annu Diabetol Hotel Dieu (1976) 0.75
[Low HDL cholesterol in close relatives and patients with myocardial infarct]. Schweiz Med Wochenschr (1978) 0.75
High density lipoprotein (HDL) subfractions in cardiovascular patients with low levels of HDL-cholesterol. Influence of hypertriglyceridaemia on subfraction concentration and composition. Atherosclerosis (1988) 0.75
[Serum lipoproteins in family members of myocardial infarct victims]. Soz Praventivmed (1978) 0.75
[Clinical study on the relationship between diabetes, hyperlipoproteinemia and atheromatosis]. Schweiz Med Wochenschr (1973) 0.75
[Teaching and Treatment Unit in the Division of Diabetology (Geneva)]. Rev Med Suisse Romande (1980) 0.75
[Coronary atherosclerosis and serum lipoproteins]. Schweiz Med Wochenschr (1979) 0.75
[Classification of hyperlipoproteinemia in the light of advances in pathogenetic studies]. Pol Tyg Lek (1985) 0.75
A novel high-density lipoprotein particle and associated protein in rat plasma. Biochim Biophys Acta (1990) 0.75
[Relation between HDL cholesterol and fasting glycemia in a normal population and a diabetic group]. Schweiz Med Wochenschr (1984) 0.75
[Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)]. Nouv Presse Med (1980) 0.75
[Influence of hormonal contraception on serum lipoproteins]. Schweiz Med Wochenschr (1978) 0.75
[Cholesterol and triglycerides of serum lipoproteins isolated by means of ultracentrifugation. Correlation with arteriosclerosis]. Schweiz Med Wochenschr (1974) 0.75
Lipid, lipoprotein and APO-A and APO-B lipoprotein distribution in Italian and Swiss schoolchildren. The Geneva survey. Pediatr Res (1982) 0.75
[Dietary treatment of the hyperlipidemias]. Ther Umsch (1986) 0.75
[Procetofen in the treatment of hyperlipoproteinaemias (author's transl)]. Schweiz Rundsch Med Prax (1980) 0.75
[The general practitioner confronted with hypercholesteremia]. Schweiz Rundsch Med Prax (1970) 0.75
[Drug therapy of hyperlipemia. Role of drugs at the disposition of general practitioners]. Ther Umsch (1970) 0.75
Treatment of systemic lupus erythematosus (SLE) with immunosuppressive drugs 1: An analysis of immunologic data. Helv Med Acta (1967) 0.75
[HDL-cholesterol and family incidence of coronary disease in the Genevan population]. Schweiz Med Wochenschr (1983) 0.75
[Diabetic microangiopathy, early or late manifestation of the disease? Electron microscopy study of muscular capillaries]. Helv Med Acta Suppl (1970) 0.75
[Molecular pathophysiology of familial hypercholesterolemia]. Pol Tyg Lek (1985) 0.75
[Dyslipidemias and atherosclerosis. Treatment strategy]. Schweiz Rundsch Med Prax (1986) 0.75
Actin stress fiber content of regenerated endothelial cells correlates with intramural retention of intermediate plus low density lipoproteins in rat aorta after balloon injury. Atherosclerosis (1989) 0.75
Capillary basement membrane thickness in early diabetes. Adv Metab Disord (1973) 0.75
Diabetic retinopathy: study of the action of O-betahydroxyethyl-rutosides (HR) by retinal fluoresceinography. Diabetologia (1970) 0.75
[Treatment of systemic lupus erythematosus with antimetabolites. Relations between the clinical course and immunological reactions]. Helv Med Acta (1967) 0.75
[Remnant disease associated with apoprotein E1; clinical importance of apoprotein E (apo E) phenotypes]. Schweiz Med Wochenschr (1989) 0.75
[Effect of renal insufficiency on diabetes mellitus]. Rev Med Suisse Romande (1979) 0.75
[Reversible acquired acanthocytosis and hemolytic anemia associated with hypobetalipoproteinemia in a chronic alcoholic]. Schweiz Med Wochenschr (1983) 0.75
[Diabetic retinopathy: study on the action of l'o-beta-hydroxyethylrutoside for retinal fluoresceinography]. Helv Med Acta Suppl (1969) 0.75
[Lipoprotein metabolism and atherosclerosis]. Schweiz Rundsch Med Prax (1988) 0.75
[Why change the fat content of diabetic diets?]. Rev Med Suisse Romande (1973) 0.75
[Study of glucose tolerance and insulin secretion (IRI) in familial hemochromatosis]. Helv Med Acta (1972) 0.75
A non-competitive enzyme-linked immunosorbent assay for measuring human plasma apolipoprotein B levels. Clin Chim Acta (1985) 0.75
[Plasma lipoproteins. Influence of heredity and external factors in the genesis of dyslipidemias]. Rev Med Suisse Romande (1980) 0.75
[Vascular complications of diabetes]. Ther Umsch (1967) 0.75
[Dyslipidemia in diabetes mellitus: significance, diagnosis and treatment]. Schweiz Rundsch Med Prax (1990) 0.75
Epitope expression in purified and lipid-bound forms of human apoprotein A-I. Adv Exp Med Biol (1987) 0.75
[Factors influencing the rate of elimination of injected fat emulsions (Intralipid) in healthy subjects and in patients with coronary disease]. Schweiz Med Wochenschr (1976) 0.75